#### 1 Co-detection of respiratory pathogens in patients hospitalized with Coronavirus

## 2 viral disease-2019 pneumonia

- 3 María Luisa Blasco<sup>a</sup>, Javier Buesa<sup>b,c</sup>, Javier Colomina<sup>b</sup>, María José Forner<sup>d,e</sup>, María José
- 4 Galindo<sup>d,e</sup>, Jorge Navarro<sup>f</sup>, José Noceda<sup>g</sup>, Josep Redón<sup>d,e</sup>, Jaime Signes-Costa<sup>h</sup>, and
- 5 David Navarro<sup>b,c#</sup>
- <sup>1</sup>Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research
- 7 Institute, Valencia, Spain.
- 8 <sup>2</sup>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,
- 9 Valencia, Spain.
- <sup>3</sup>Department of Microbiology, School of Medicine, University of Valencia, Valencia,
- 11 Spain.
- <sup>4</sup>Internal Medicine Department, Clinic University Hospital, INCLIVA Health Research
- 13 Institute, Valencia, Spain.
- <sup>5</sup>Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
- <sup>6</sup>Medical Directory, Clinic University Hospital, INCLIVA Health Research Institute,
- 16 Valencia, Spain.
- <sup>17</sup> <sup>7</sup>*Emergency Medical Service, Clinic University Hospital, Valencia, Spain.*
- <sup>8</sup>Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute,
- 19 Valencia, Spain.
- 20
- 21 **Running title:** Co-infection with respiratory pathogens in Covid-19.
- <sup>#</sup>Correspondence: David Navarro, Microbiology Service, Hospital Clínico
  Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
  Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010

25 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
26 david.navarro@uv.es.

27

## 28 ABSTRACT

29 There is scarce information on the frequency of co-detection of respiratory pathogens 30 (RP) in patients with Covid-19. Documentation of coinfections in Covid-19 pneumonia 31 patients may be relevant for appropriate clinical and therapeutic management of 32 patients. Between March 4th and March 28th, 2020, a total of 183 adult patients testing 33 positive by SARS CoV-2 RT-PCR on respiratory specimens were hospitalized with 34 interstitial pneumonia at our center, of whom 103 were tested for other RP by a 35 multiplexed PCR assay. Three patients had a positive result for either one (n=2); 36 Coronavirus HKU1 or Mycoplasma pneumoniae) or two targets (n=1; Influenza virus A 37 (H3) and Respiratory syncytial virus B). Twenty-three patients testing negative by 38 SARS CoV-2 RT-PCR and presentig with clinical, laboratory findings and imaging 39 compatibe with Covid-19 pneumonia underwent RP screening. Of these, 6 (26%) had a 40 positive result for a single RP. Our data indicate that despite the apparent rarity of 41 coinfections in patients with Covid-19 pneumonia, routine testing for RP should be 42 advised, since agents for which specific therapy can be prescribed may be detected.

- 43
- 44

45

46

48

49 Clinical, laboratory and imaging characteristics of Coronavirus disease 2019 (Covid-19) 50 and risk factors associated with poor outcomes have been reported in various studies (1-51 5). Information on whether other respiratory pathogens (RP) were co-detected in these 52 patients was not provided, despite the fact that coinfection with RP has been reported to 53 occur in this clinical setting (6-9). Documentation of coinfections in Covid-19 54 pneumonia patients may be relevant not only for appropriate clinical and therapeutic 55 management of patients, but also to precisely characterize disease features and delineate 56 risk factors potentially impacting on clinical outcomes. Here, we report on our 57 experience on this topic, gathered between March 4th and March 28th, 2020, at the 58 Clinic University Hospital of Valencia, a tertiary teaching hospital with 586 beds which 59 serves Clínico-Malvarrosa Health Department (attending 368.000 inhabitants in the 60 northeast of the city). The study was approved by the Ethical Committee of University 61 Clinic Hospital, INCLIVA, Valencia. Informed consent was not requested as laboratory 62 analyses reported herein were conducted routinely in our patients following local 63 guidelines.

64 A total of 183 adult patients testing positive by SARS CoV-2 RT-PCR on respiratory 65 specimens were hospitalized with interstitial pneumonia, of whom 103 (64 males/39 66 females; median age, 64 years; range, 19-100 years) were tested for other RP by a 67 multiplexed PCR assay (10) (Table 1). Three patients (2.9%) had positive results for 68 either one (n=2; Coronavirus HKU1 or *Mycoplasma pneumoniae*) or two targets (n=1; Influenza virus A (H3) and Respiratory syncytial virus B). Twenty-three patients (14 69 70 males/9 females; median age, 54 years; range, 31-79 years) testing negative by SARS 71 CoV-2 RT-PCR in a single respiratory specimen, presentig with clinical, laboratory

findings and imaging compatibe with Covid-19 pneumonia (1-5) underwent RP
screening. Of these, 6 (26%) had a positive result for a single RP.

74 Coinfection with RP in adult patients with respiratory tract infections occurs commonly 75 (11,12). In line with this, coinfection with RP was observed in 2 out of 12 patients 76 (25%) presenting with upper or lower respiratory tract infections and no clinical 77 suspicion of Covid-19 and testing positive for RP within the study period. The rate of 78 co-detection of RP in the same time period of the preceding year was rather comparable 79 (6 out of 18 patients testing positive for RP; 35%). Nevertheless, patients with Covid-19 80 pneumonia were found to be infrequently coinfected with other RP; this phenomenom 81 could have been underestimated, since 26% of patients fulfilling criteria of this clinical 82 entity (1-5) and testing negative by SARS CoV-2 RT-PCR, had RP detected in 83 respiratory specimens. In this sense, false negative SARS CoV-2 PCR results in upper 84 respiratory tract specimens occurs (13). The possibility of a viral interference 85 phenomenon similar to that described for influenza virus A (sub)types should also be 86 considered (14). Despite the apparent rarity of coinfections in patients with Covid-19 87 pneumonia, routine testing for RP should be advised, since agents for which specific 88 therapy can be prescribed (i.e Mycoplasma pneumoniae, Influenza virus A, or 89 Respiratory syncytial virus) may be detected. This approach may have a benefitial 90 impact on patient survival.

#### 91 Funding

92 The current work received no public or private funding.

- 93 **Conflicts of Interest**
- 94 The authors declare no conflicts of interest
- 95 Acknowledgements

- 96 We are grateful to all personnel who work at Clinic University Hospital for their
- 97 dedicated and tireless effort in the fight against Covid-19.

## 98 **REFERENCES**

- 99 1. Wang Z, Yang B, Li Q, Wen L, Zhang R. 2020. Clinical Features of 69 Cases with
- 100 Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis; Mar 16. pii: ciaa272. doi:
- 101 10.1093/cid/ciaa272. [Epub ahead of print].
- 102 2. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, Xiong Y, Cheng Z, Gao S,
- 103 Liang K, Luo M, Chen T, Song S, Ma Z, Chen X, Zheng R, Cao Q, Wang F, Zhang
- 104 Y. 2020. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China.
- 105 Clin Infect Dis; Mar 16. pii: ciaa270. doi: 10.1093/cid/ciaa270. [Epub ahead of print].
- 106 3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z,
- 107 Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. 2020. Clinical Characteristics of 138
- 108 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
- 109 China. JAMA; Feb 7. doi: 10.1001/jama.2020.1585. [Epub ahead of print].
- 110 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X,
- 111 Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical
- 112 course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,
- 113 China: a retrospective cohort study. Lancet; Mar 28;395(10229):1054-1062. doi:
- 114 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
- 115 5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui
- 116 DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY,
- 117 Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P,
- 118 Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong

- 119 NS. 2020. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J
- 120 Med; Feb 28. doi: 10.1056/NEJMoa2002032. [Epub ahead of print].

# 121 6. Wu X, Cai Y, Huang X, u X, Zhao L, Wang F, Li Q, Gu S, Xu T, Li Y, Lu B,

- 122 Zhan Q. 2020. Co-infection with SARS-CoV-2 and influenza A virus in patient with
- 123 pneumonia. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with
- 124 Pneumonia, China. Emerg Infect Dis;Mar 11;26(6). doi: 10.3201/eid2606.200299.
- 125 7. Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, Guo Y, Dai Y, Xu Y, Cai Y, Chen
- 126 X, Zhang Z, Huang K. 2020. Co-infections of SARS-CoV-2 with multiple common
- 127 respiratory pathogens in infected patients. Sci China Life Sci 2020; 63,
- 128 http://doi.org/10.1007/s11427-020-1668-5.
- 129 8. Touzard-Romo F, Tapé C, Lonks JR. 2020. Co-infection with SARS-CoV-2 and
- 130 Human Metapneumovirus I Med J (2013);Mar 19;103(2):75-76.
- 131 9. Fan BE, Lim KGE, Chong VCL, Chan SSW, Ong KH, Kuperan P. 2020.
- 132 COVID-19 and Mycoplasma pneumoniae coinfection. Am J Hematol; Mar 15. doi:
- 133 10.1002/ajh.25785. [Epub ahead of print].
- 134 10. Costa E, Rodríguez-Domínguez M, Clari MÁ, Giménez E, Galán JC, Navarro
- D. 2015. Comparison of the performance of 2 commercial multiplex PCR platforms for
  detection of respiratory viruses in upper and lower tract respiratory specimens. Diagn
  Microbiol Infect Dis;82:40-43.
- 138 11. Tanner H, Boxall E, Osman H. 2012. Respiratory viral infections during the 2009-
- 139 2010 winter season in Central England, UK: incidence and patterns of multiple virus co-
- 140 infections Eur J Clin Microbiol Infect Dis;31:3001-3006.

- 141 12. To KKW, Chan KH, Ho J. 2019. Respiratory virus infection among hospitalized
- 142 adult patients with or without clinically apparent respiratory infection: a prospective
- 143 cohort study. Clin Microbiol Infect;25:1539-1545.
- 144 13. Winichakoon P, Chaiwarith R, Liwsrisakun C, Salee P, Goonna A, Limsukon
- 145 A, Kaewpoowat Q. 2020. Negative Nasopharyngeal and Oropharyngeal Swab Does
- 146 Not Rule Out COVID-19. J Clin Microbiol; Feb 26. pii: JCM.00297-20. doi:
- 147 10.1128/JCM.00297-20. [Epub ahead of print].
- 148 14. Schultz-Cherry S. 2015. Viral Interference: The Case of Influenza Viruses. J Infect
- 149 Dis 212:1690-1691.
- 150

.

 TABLE 1. Detection of respiratory pathogens by multiplexed PCR in the study

 patients

Respiratory pathogens <sup>a</sup>	Patients				
	SARS	SARS CoV-2	Respiratory	Respiratory	
	CoV-2	negative with	infections	infections in	
	positive	clinical,	with no	season 2019	
	(n=103) <sup>b</sup>	laboratory and	suspicion of	(n=50) <sup>e</sup>	
		imaging	Covid-19		
		compatible	$(n=48)^{d}$		
		with Covid-19			
		(n=23) <sup>c</sup>			
One target	2	6	10	12	
Adenovirus	0	0	1	0	
Coronavirus HKU1	1	0	0	0	
Coronavirus 229E	0	0	0	2	

Coronavirus OC43	0	0	2	0	
Coronavirus NL63	0	0	0	0	
Human Bocavirus	0	0	0	0	
Human Metapneumovirus	0	0	1	1	
Influenza virus A	0	1	1	2	
Mycoplasma pneumoniae	1	0	0	0	
Parainfluenza virus 3	0	0	0	1	
Respiratory Syncytial virus	0	1	0	0	
(A/B)					
Rhinovirus-Enterovirus	0	4	5	6	
Two targets	1	0	2	6	
Adenovirus/Influenza virus A	0	-	0	2	
(H3)					
Coronavirus 229E/Coronavirus	0	-	0	1	
NL63					
Coronavirus 229E/Rhinovirus-	0	-	0	1	
Enterovirus					
Human	0	-	2	0	
Metapneumovirus/Coronavirus					
229E					
Human Metapneumovirus/	0	-	0	2	
Parainfluenza virus 3					
Influenza virus A	1	-	0	0	
(H1)/Respiratory syncytial					
virus A					
Naso and oropharyngeal swabs were collected with flocked swabs in universal transport					

medium (Beckton Dickinson, Sparks, MD,USA, or Copan Diagnostics, Murrieta, CA, USA). Tracheal aspirates, sputa and bronchoalveolar lavage fluids were transported undiluted. Specimens were received at the laboratory within 30 min of collection and were conserved at 4 ° C until processed (within 6 hours). Nucleic acid extraction was performed using the Qiagen EZ-1 Viral extraction kit or the DSP virus Pathogen Minikit on the EZ1 or QiaSymphony Robot instruments (Qiagen, Valencia, CA, USA), respectively.

<sup>a</sup>As determined by the NxTAG® Respiratory Pathogen Panel (Luminex Corp, Austin, Tx, USA), which includes the following targets: Adenovirus, Influenza A, Influenza A (H1), Influenza A (H3), Influenza B, Parainfluenza virus 1-4, Coronavirus HKU1, NL63,229E, OC43, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Human Metapneumovirus, Human Bocavirus, Rhinovirus-Enterovirus, *Chlamydophila pneumoniae* and *Mycoplasma pneumoniae*.

<sup>b</sup>Several commercially available assays were used for SARS CoV-19 detection, including the LightMix® Modular SARS and Wuhan CoV E-gene/LightMix® Modular Wuhan CoV RdRP-gene from TIB MOLBIOL GmHD, distributed by Roche Diagnostics (Pleasenton, CA, USA) on the Light Cycler 2.0 instrument, the SARS-COV-2 REALTIME PCR KIT from Vircell Diagnostics (Granada, Spain) or the REALQUALITY RQ-2019-nCoV from AB ANALITICA (Padua, Italy), both on the Applied Biosystems 7500 instrument. Detection of two SARS Cov-2 viral gene targets was considered a positive result. Respiratory specimens tested were the following: nasopharyngeal exudates (n=60), nasopharyngeal aspirates (n=21), oropharyngeal exudates (n=17), tracheal aspirates (n=3), and sputa (n=2).

<sup>c</sup>Respiratory specimens tested were the following: nasopharyngeal aspirates (n=14), nasopharyngeal exudates (n=4), tracheal aspirates (n=3), sputum (n=1), and bronchoalveloar lavage fluid (n=1).

<sup>d</sup>Patients in this group (31 males/17 females; median age, 61 years; range, 24-84 years) were screened for RP in respiratory specimens. In our center, as per protocol, oncohematological patients with upper or lower respiratory tract infections and hospitalized patients with penumonia of probable viral origin are routinely tested for RP. Respiratory specimens tested from these patients were the following: nasopharyngeal aspirates (n=18), nasopharyngeal exudates (n=9), tracheal aspirates (n=8), sputa (n=4), and bronchoalveloar

# lavage fluids (n=9).

	<sup>e</sup> Patients in this group (28 males/22 females; median age, 58 years; range, 19-78 years)
	were screened for RP in respiratory specimens as per protocol (as detailed above).
	Respiratory specimens tested were the following: nasopharyngeal aspirates (n=24),
	nasopharyngeal exudates (n=5), tracheal aspirates (n=8), sputa (n=3), and bronchoalveloar
	lavage fluids (n=10).
151	
152	
153	
154	
155	
155	
156	
1 - 7	
157	
158	
159	
160	
161	